TLSI
TriSalus Life Sciences, Inc.·Healthcare
4.35
3.081%(+0.13)
Close PriceLast Updated: — ET
52W L: $3.4252W H: $7.95
TLSI NEWS
businesswire.com
4d ago
TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced its participation in the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting, taking place April 11–15, 2026, in Toronto, Ontario, Canada. TriSalus will showcase new clinical a.
businesswire.com
Apr 7
TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces the appointment of Richard Marshall, M.D., as Chief Medical Officer on a full-time basis, effective June 29, 2026. Dr. Marshall will transition into the role from his current position as Medical Di.
defenseworld.net
Mar 23
Insider Selling: TriSalus Life Sciences (NASDAQ:TLSI) CEO Sells $17,998.54 in Stock
TriSalus Life Sciences, Inc. (NASDAQ: TLSI - Get Free Report) CEO Mary Szela sold 4,358 shares of the firm's stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $4.13, for a total value of $17,998.54. Following the completion of the transaction, the chief executive officer owned 768,931 shares
businesswire.com
Mar 18
TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced the publication of preclinical research evaluating Pressure-Enabled Drug Delivery™ (PEDD™) of nelitolimod in liver tumor models in Frontiers in Oncology. The study evaluated the delivery and biologic activity.
seekingalpha.com
Mar 5
TriSalus Life Sciences, Inc. (TLSI) Q4 2025 Earnings Call Transcript
TriSalus Life Sciences, Inc. (TLSI) Q4 2025 Earnings Call Transcript
businesswire.com
Mar 5
TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter and year ended December 31, 2025, and provides an operational update. “During our fourth quarter and throughout 2025, we continued to deliver strong commercial performance, su.
